Syndicated Research Studies

The global gene therapy market was valued at approximately USD 5.54 billion in 2023 and is projected to experience significant growth at a compound annual growth rate (CAGR) of 18.88% from 2024 to 2030. This growth is driven by several key factors, including the expanding scope of advanced therapies, innovations in gene delivery technologies, and the increasing competition among leading companies focused on commercializing their gene therapies. Biotechnology companies are also making strategic moves such as acquisitions, mergers, collaborations, and partnerships to enhance their in-house expertise and strengthen their product development pipelines. The market's growth is further supported by a robust pipeline of gene therapy products currently under development. Research efforts are focused on making gene therapies more widely available in clinical settings, with numerous universities and research institutes developing a wide range of products. This extensive pipeline is expected ...

The global gene therapy market was valued at USD 5.54 billion in 2023 and is projected to experience a robust compound annual growth rate (CAGR) of 18.88% from 2024 to 2030. This growth is driven by several key factors, including the expanding field of advanced therapies, continuous advancements in gene delivery technologies, and the growing competition among major players in the market. These companies are aggressively pursuing strategies such as acquisitions, mergers, collaborations, and partnerships to bolster their in-house expertise, strengthen their product pipelines, and accelerate the development and commercialization of gene therapies. However, the COVID-19 pandemic has had a considerable negative impact on the gene therapy market's growth. The pandemic disrupted multiple aspects of the sector, including the supply of essential materials, manufacturing processes, and logistics operations. Companies faced significant delays in the delivery of key components and experienced...

The global gene therapy market was estimated at USD 5.54 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 18.88% from 2024 to 2030. Several factors contribute to this market growth, including the expanding field of advanced therapies, advancements in gene delivery technologies, and increasing competition among key players aiming to commercialize their therapies. Biotechnology companies are actively engaging in strategies such as acquisitions, mergers, collaborations, and partnerships to enhance their in-house expertise and strengthen their product pipelines. However, the COVID-19 pandemic has adversely affected the growth of the gene therapy market. This sector faced significant disruptions due to the pandemic, leading to considerable challenges in the supply of materials, manufacturing processes, and logistics operations. For example, companies experienced prolonged delivery times for essential components. Additionally, they encountered shortages in ...

Gene Therapy Industry Overview The global  gene therapy market  size is expected to reach USD 10.0 billion by 2028 registering a CAGR of 20.4% during the forecast period, according to a new report by Grand View Research, Inc. The market growth is attributed to the increasing prevalence of cancer coupled with the lack of effective treatment for the disease. Constant expansion of cancer genetic studies has deciphered relevant information about cancer-related molecular signatures. This has driven the clinical trials for advanced cancer therapeutics, thereby driving the market growth. In addition, expansion of this mode of treatment in non-cancer applications with approval of therapies, such as approval of Bluebird Bio’s Zynteglo in June 2019 for β-thalassemia and others, demonstrates the shift in the preferences of companies towards other unsaturated segments. Gene Therapy Market Segmentation Grand View Research has segmented the global gene therapy market on the...